From Bespoke to Scalable: AI in Cell and Gene Therapy
As cell and gene therapies (CGTs) continue to revolutionise treatment for cancer and rare diseases, the industry grapples with challenges surrounding development costs and limited patient access. AI is emerging as a transformative force, streamlining operations, accelerating diagnosis and enabling dynamic, personalised engagement with patients and providers.
Download this latest paper to unlock real-world applications >>>
Key learnings and takeaways include:
- AI-Powered Orchestration: Discover how AI is managing CGT logistics from complex supply chains to real-time scheduling.
- Empowering Field Teams: Learn how AI-generated insights are transforming field teams into strategic partners who build trust and navigate complexity.
- Human-AI Collaboration: Understand why combining AI with human empathy is key to unlocking competitive advantage in CGT.
- Expert Perspectives: Hear from pharma leaders, like Caspar Gøtsche, Global Medical Director, Cell and Gene Therapy, Bayer surrounding the positive uptake of AI: “In my world, there’s little fear of AI; what I see instead is curiosity and a real desire to improve the technology by using it”
Don’t miss this latest read, download now to discover how AI is driving scalable personalisation in CGT and why staying ahead is crucial >>>
Many thanks,
Reuters Events is part of Reuters News & Media Ltd, 5 Canada Square, Canary Wharf, London, E14 5AQ. Registered in England and Wales: 2505735.